South Korea's Seoul Composite Index rose to 1%.The tenth batch of national procurement officially opened, and the number of enterprises and varieties involved reached a record high. The tenth batch of centralized drug procurement organized by the state officially accepted the application materials of enterprises at 8: 00 this morning at No.398 Zhanyuan Road, Nanqiao New Town, Fengxian District, Shanghai. This centralized procurement involved 62 varieties and 263 product specifications, and the number of enterprises and varieties involved reached a record high. Among them, 33 enterprises competed for nine short-listed oral sustained-release formulations of sitagliptin. There are also a number of varieties that are billions in the market of public hospitals, such as doxorubicin hydrochloride liposome injection, cefoperazone injection, piperacillin injection, compound α -ketoacid oral sustained-release dosage form, norepinephrine injection and aspirin oral sustained-release dosage form. The sales scale in sample hospitals last year all exceeded 2 billion yuan. Hengrui Pharma, Kelun Pharmaceutical, Unacon and Zhengda Tianqing participated with many varieties. Note: According to the tenth batch of national adoption documents released before, the tenth batch of national adoption rules have changed a lot, such as canceling the protection mechanism of 50% price reduction and increasing the fuse recovery mechanism by 1.8 times, and the number of B-certified enterprises affects the number of final finalists.In the first 11 months of the North Stock Exchange, the issuance scale of new shares decreased by nearly 770% year-on-year, and the new shares rose by over 100% on the first day. Statistics show that from January to November, 2024, there were 20 new shares listed on the North Stock Exchange, and the total amount of funds raised was about 4.175 billion yuan, down by nearly 70% year-on-year. The scale of new shares is generally small, and the number of new shares raised less than 200 million yuan accounts for 65% of the total number of new shares. The share price of 70% new shares rose over 100% on the first day of listing. Among them, the share price of Tongguan Mining Construction rose by 731.41% on the first day of listing, and the share prices of Shengye Electric, Keli and Wanyuantong rose by over 300% on the first day. In terms of underwriters, in the first November of 2024, the number of projects underwritten by CITIC Jiantou Securities was the highest, with a total project scale of about 699 million yuan, followed by First Venture Securities and Minsheng Securities. (Xinhua Finance)
Yin Xiyue stayed in the office for 30 minutes and then returned to her residence. (Yonhap News Agency)Citic Jiantou: We are optimistic about the investment opportunities in the pharmaceutical industry in 2025, focusing on the opportunities of new increase and industry integration. Citic Jiantou Securities reported on December 11th that looking forward to 2025, the reform policy in the pharmaceutical field has been normalized, and the most noteworthy incremental policy in the medical insurance field is to establish a diversified payment system. The medical field is about to usher in the reform of "deep water areas" such as salary system and graded diagnosis and treatment, which is in line with expectations on the whole. At the same time, the innovation of China's pharmaceutical industry has gradually stepped onto the international stage, some sub-sectors will be marginally improved, and industry integration will begin. We are optimistic about the investment opportunities in the pharmaceutical industry in 2025. It is suggested to focus on the new increase (innovation, going out to sea, marginal change) and industry integration opportunities.Australia's ASX 200 index narrowed to 0.1%, and the Australian dollar increased. The just released Australian employment data was better than expected.
Shengmei Shanghai issued a statement on the new US export control regulations. Shengmei Shanghai issued a statement on the new US export control regulations, saying that on December 2, the BIS of the US Department of Commerce issued new control measures for semiconductors exported and transferred to People's Republic of China (PRC) (China), covering advanced integrated circuit (IC) products, specific integrated circuit manufacturing equipment and technology, and supercomputers related to artificial intelligence (AI) and advanced computing. According to the new regulations, Shengmei Shanghai and its domestic and Korean subsidiaries are included in the BIS entity list. ACM Research, Inc and its direct subsidiaries outside Chinese mainland are not included in the list. The company is comprehensively evaluating the potential impact of the new regulations on the company's business and operation plans. Based on the current information, the company believes that as the company has established diversified supply chains and alternative resources, the impact on the delivery and service capacity of equipment produced by Shengmei Shanghai and sold to domestic customers will be controllable and manageable. The new regulations will not affect the company's product sales, delivery and service capabilities to overseas customers. Consistent with previous years, the company plans to voluntarily disclose the announcement of 2024 annual operating results and 2025 annual operating results forecast in January 2025.South Korean President Yin Xiyue will speak to the people again. The reporter learned on the 12th local time that South Korean President Yin Xiyue will speak to the people again. (CCTV News)Rosario Grain Exchange: Argentina's wheat production in 2024/25 is estimated to be 19.3 million tons, compared with the previous estimate of 18.8 million tons.